Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


1 Am J Hematol
2 Blood
2 BMC Cancer
1 Eur J Haematol
11 Leuk Lymphoma
2 Leuk Res
3 Leukemia
1 Oncol Rep

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Hematol

  1. SASAKI K, Kadia T, Begna K, DiNardo CD, et al
    Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
    Am J Hematol. 2021 Oct 30. doi: 10.1002/ajh.26395.
    PubMed         Abstract available


  2. FENG Y, Feng W
    Numerous ring sideroblasts in chronic neutrophilic leukemia.
    Blood. 2021;138:1783.

  3. HEUSER M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al
    2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
    Blood. 2021 Nov 1. pii: 477736. doi: 10.1182/blood.2021013626.
    PubMed         Abstract available

    BMC Cancer

  4. HALLAL M, Braga-Lagache S, Jankovic J, Simillion C, et al
    Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
    BMC Cancer. 2021;21:789.
    PubMed         Abstract available

  5. YU F, Gajendran B, Wang N, Sample KM, et al
    ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes.
    BMC Cancer. 2021;21:680.
    PubMed         Abstract available

    Eur J Haematol

    Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Eur J Haematol. 2021 Oct 30. doi: 10.1111/ejh.13722.
    PubMed         Abstract available

    Leuk Lymphoma

  7. SHIMONY S, Yeshurun M, Wolach O, Ram R, et al
    Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
    Leuk Lymphoma. 2021;62:2475-2481.
    PubMed         Abstract available

  8. RAMAN I, Pasricha SR, Prince HM, Yannakou CK, et al
    Management of hydroxyurea resistant or intolerant polycythemia vera.
    Leuk Lymphoma. 2021;62:2310-2319.
    PubMed         Abstract available

  9. JACOBY MA, Finn L, Emadi A, Saba NS, et al
    Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
    Leuk Lymphoma. 2021;62:2539-2542.

  10. ALHALLAK K, de la Puente P, Jeske A, Sun J, et al
    3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
    Leuk Lymphoma. 2021;62:2457-2465.
    PubMed         Abstract available

  11. PATNAIK MM, Mughal TI, Brooks C, Lindsay R, et al
    Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
    Leuk Lymphoma. 2021;62:2568-2586.
    PubMed         Abstract available

  12. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed         Abstract available

  13. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    PubMed         Abstract available

  14. RIDGE SM, Whiteley AE, Yao H, Price TT, et al
    Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.
    Leuk Lymphoma. 2021;62:2690-2702.
    PubMed         Abstract available

    The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL.
    Leuk Lymphoma. 2021;62:2299-2302.

  16. ARUMUGAM JR, Bommannan K, Radhakrishnan V, Sagar TG, et al
    Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Leuk Lymphoma. 2021 Nov 2:1-9. doi: 10.1080/10428194.2021.1992755.
    PubMed         Abstract available

  17. DA CUNHA-BANG C, Kirkby NS, Friis-Hansen L, Niemann CU, et al
    Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Nov 2:1-3. doi: 10.1080/10428194.2021.1973673.

    Leuk Res

  18. BAGHAEI VAJI F, Boroumand Nasr A, Rezvani A, Ayatollahi H, et al
    Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
    Leuk Res. 2021;111:106729.
    PubMed         Abstract available

  19. CHOW S, Tang K, Al-Abri M, Hall V, et al
    RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2021;111:106735.


  20. KLOOS A, Mintzas K, Winckler L, Gabdoulline R, et al
    Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
    Leukemia. 2021 Nov 2. pii: 10.1038/s41375-021-01459.

  21. BURKE MJ, Devidas M, Chen Z, Salzer WL, et al
    Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232.
    Leukemia. 2021 Nov 1. pii: 10.1038/s41375-021-01460.
    PubMed         Abstract available

  22. YANG M, Pan Z, Huang K, Busche G, et al
    A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.
    Leukemia. 2021 Nov 3. pii: 10.1038/s41375-021-01452.
    PubMed         Abstract available

    Oncol Rep

  23. GENG Y, Wu W, Zhou L, Li J, et al
    Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
    Oncol Rep. 2021;45.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.